Rosetta Genomics said this week that it has signed a deal making Genekor the exclusive distributor of its three microRNA-based diagnostics in Greece.
Under the deal, Genekor will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.
In October, Rosetta inked a deal giving Australia's Genetic Technologies the rights to sell the tests in Australia, New Zealand, and Singapore.
The month before, the Italian rights to the diagnostics were licensed to AXA Diagnostics. Before that, the company licensed the tests' rights in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories, and the Canadian market rights to Warnex Medical Laboratories.
Before that, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests, and the Israeli and Turkish rights to Teva Pharmaceuticals.